Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced …
Sep 12, 2024 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the results of an interim analysis from a second pivotal Phase 3 clinical trial investigating the use of the company’s twice-yearly injectable HIV-1 …
Twice-yearly shot proves successful at preventing HIV infection …
Jul 24, 2024 · The twice-yearly injection of the drug lenacapavir can provide total protection against HIV infections, demonstrating 100% efficacy in Phase 3 trial data released by drugmaker Gilead and...
Long-acting injectable lenacapavir continues to show promising …
Sep 26, 2024 · WHO welcomes the latest findings from the PURPOSE-2 trial on long-acting injectable lenacapavir (LEN) for HIV prevention. An interim analysis, announced on 12 September 2024, demonstrated the drug’s remarkable efficacy in preventing HIV.
An injectable HIV-prevention drug is highly effective - NBC News
Thrilled over the news Thursday that lenacapavir was 89% more effective at preventing HIV than daily oral preventive medication among gay, bisexual and transgender people, plus previous...
Twice-a-year injection reduced risk of HIV infection by 96%, drug …
Sep 12, 2024 · In a Phase 3 clinical trial, 99.9% of participants who took a twice-a-year injection of lenacapavir for HIV prevention did not acquire an infection, according to data from drugmaker Gilead...
New HIV drug can only offer hope of ending AIDS if all have …
GENEVA, 10 July 2024— UNAIDS has welcomed the release of Gilead Sciences’ trial results on the injectable long-acting HIV medicine Lenacapavir for HIV prevention.
Gileads Twice Yearly Lenacapavir Demonstrated 100 Efficacy and ...
Jun 20, 2024 · The results demonstrated superiority of twice-yearly lenacapavir over bHIV (primary endpoint, incidence 2.41 per 100 person-years) and superiority of twice-yearly lenacapavir over once-daily Truvada (secondary endpoint), with p<0.0001 for both endpoints.
Long-acting injectable lenacapavir proves effective in HIV …
Jul 26, 2024 · WHO welcomes the news that long-acting injectable lenacapavir as pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV acquisition in women. This represents a significant breakthrough in HIV prevention.
Full Efficacy and Safety Results for Gilead Investigational Twice ...
Jul 24, 2024 · Detailed data from the trial’s interim analysis announced in June showed that lenacapavir, the company’s twice-yearly injectable HIV-1 capsid inhibitor, demonstrated zero infections, 100% efficacy and superiority to background HIV incidence for the investigational use of HIV prevention in cisgender women (women assigned female at birth).
NIH Statement on Preliminary Efficacy Results of Twice-Yearly ...
Jun 26, 2024 · The injectable antiretroviral drug lenacapavir was safe and 100% effective as long-acting HIV pre-exposure prophylaxis (PrEP) among cisgender women in a Phase 3 clinical trial, according to top-line findings released by Gilead Sciences, Inc., the study sponsor.